Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
本文描述了赖
氨酸特异性去甲基化酶-1
抑制剂4-[2-(
4-氨基哌啶-1-基)-5-(3-
氟-4-
甲氧基苯基)-1-甲基-6-氧代-1,6-二氢
嘧啶-4-基]-
2-氟苯腈的药学上可接受的盐的无定形和结晶形式。还描述了适用于哺乳动物的药物组合物,其中包括赖
氨酸特异性去甲基化酶-1
抑制剂,以及使用赖
氨酸特异性去甲基化酶-1
抑制剂治疗与赖
氨酸特异性去甲基化酶-1活性相关的疾病或病症的方法。